Navigation Links
Study finds 'rescue course' of antenatal steroids improves outcome in premature babies
Date:1/29/2009

WASHINGTON, DC In a study to be presented today at the Society for Maternal-Fetal Medicine's (SMFM) annual meeting, researchers will unveil findings that show that premature babies born before 34 weeks have a 31 percent reduction in serious complications when given a "rescue course" of Antenatal Corticosteroids (ACS) steroids with no adverse side effects noted.

"Premature babies are very susceptible to respiratory problems which may lead to additional severe complications," said Dr. James Kurtzman, M.D. (Associate Professor, UC Irvine Medical Center). "Antenatal steroids clearly reduce the risk of these respiratory complications."

Years ago doctors gave multiple courses of antenatal steroids to mothers who were at risk for delivering prematurely. However, certain studies found that there were possible adverse affects to multiple ACS courses because babies were found to have slightly smaller head circumferences and lower birth weights. As a result the National Institutes of Health (NIH) recommended further study.

"The effect (of the NIH recommendation) was that doctors were only giving one ACS course, and they were nervous about when to give it for the best effect. They often waited until the last minute, and some women didn't get a complete treatment or didn't get it at all," said Dr. Kurtzman. "What this study has found is that we can give women who threaten to deliver prematurely an initial ACS course, and if they remain pregnant, we can give one 'rescue course' closer to delivery. By doing so, the babies' complications are reduced by about a third with no adverse side effects found."

In this study, which took place over five years in 18 different medical centers and was supported by the Pediatrix Medical Group, 437 patients were randomized (233 in the study group, and 214 in the placebo group). The results showed a significant reduction in composite neonatal morbidity for babies born prior to 34 weeks in the "rescu
'/>"/>

Contact: Vicki Bendure
vicki@bendurepr.com
202-374-9259
Society for Maternal-Fetal Medicine
Source:Eurekalert

0

GOOD

Page: 1 2

Related biology news :

1. Brain structure assists in immune response, according to Penn vet study
2. Study finds MRSA in Midwestern swine, workers
3. New study provides further evidence that apple juice can delay onset of Alzheimers disease
4. UD research study to shed light on emerging seaborne pathogen
5. Study links water pollution with declining male fertility
6. UGA study may give hope that ivory-billed woodpeckers still around
7. Evolutionary process more detailed than previously believed, study shows
8. Researchers to use K-States BSL-3 Lab for $1 million study of fungus threatening wheat crops
9. Human beta cells can be easily induced to replicate, according to study in Diabetes
10. Primate culture is just a stones throw away from human evolution, study finds
11. Disabling enzyme allows mice to gorge without becoming obese, new study finds

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/4/2009)...r 4, 2009 Childhood obesity in the United States ...ne fourth of advertising on daytime and prime time...tinuing questions about the role television plays ... of the Journal of Nutrition Education and Behavi...n might be a large contributor to the problem. , ...
(Date:11/4/2009)...ry that deciphered the DNA codes, or genomes, of t...has joined The Genome 10K Project, an internationa...sequences on 10,000 species of animals for conduct...can not be achieved. , Participating in The Geno...the Nov. 5, 2009 issue of the Journal of Heredity...
(Date:11/4/2009)...lif., Oct. 19 Spectros, developer ... imaging devices which shed light on life-threaten...xclusive distribution deals for both its T-Stat...covered include Australia, New Zealand, The Nethe...taly, France, Spain, Portugal, Poland, Greece, Tur...
Breaking Biology News(10 mins):TV bombards children with commercials for high-fat and high-sugar foods 2TV bombards children with commercials for high-fat and high-sugar foods 3Singapore scientists join international study of 10,000 vertebrates' genomes 2Spectros Signs New International Distribution Deals 2TFAH Applauds Affordable Health Choices Act for Making Prevention a Cornerstone of Health Reform 48518 1TFAH Applauds Affordable Health Choices Act for Making Prevention a Cornerstone of Health Reform 48518 2TFAH Applauds Affordable Health Choices Act for Making Prevention a Cornerstone of Health Reform 48518 3TFAH Applauds Affordable Health Choices Act for Making Prevention a Cornerstone of Health Reform 48518 4Organogenesis Launches Regenerative Medicine College Scholarship 48514 1Organogenesis Launches Regenerative Medicine College Scholarship 48514 2Organogenesis Launches Regenerative Medicine College Scholarship 48514 3Gene Can Dampen Chemo Drug Effectiveness 48510 1
...king part in protein folding to ensure cells funct...g molecular motions provides researchers with info...hem decipher the bases of certain diseases, such a...lecular motion gone awry. , In the past, researche...clusters to run simulations. Or they had to be con...
...that a direct interaction between vitamin D and a ...ng multiple sclerosis (MS). The research, publishe...enetics , suggests that vitamin D deficiency durin...isk of the offspring developing MS later in life. ...ndition affecting young adults. More than 85,000 p...
...YSE: CSC ) announced today that it is one of 12 ...pport Services Unrestricted contract by the Depart...(BTF). The indefinite-delivery/indefinite-quantity... solutions and task orders to meet the mission nee... has a three-year base period and two one-year opt...
Other Biology News:New open-source software permits faster desktop computer simulations of molecular motion 2New open-source software permits faster desktop computer simulations of molecular motion 3Genetic study shows direct link between vitamin D and MS susceptibility 'gene' 2Genetic study shows direct link between vitamin D and MS susceptibility 'gene' 3CSC Awarded Department of Defense Biometrics Contract 2
(Date:11/6/2009)...LLEY, Calif., Nov. 6 Calbiotech, I...ll Business Innovative Research (SBIR) Phase I con...al command. Under terms of the agreement, Calbiote...or the diagnosis of Dengue virus. ,, Dengue ...s a major threat to military forces deployed to tr...
(Date:11/5/2009)...URG, Md., Nov. 5 GenVec,...al results for the third quarter ended September 3...n ($0.04 per share) for the three months ended Sep...lion ($0.08 per share) in the comparable quarter o...09, GenVec,s net loss was $14.1 million ($0.15 per...
(Date:11/5/2009)...e Call on Thursday, November 5, 2009 at 4:30 p.m. ... 5 /PRNewswire-FirstCall/ - OncoGenex Pharmaceutic... OGXI ) today reported unaudited financial results...mber 30, 2009 and reviewed the Company,s highlight...ng consolidated results reflect the operations of ...
(Date:11/5/2009)..., CA, November 5, 2009 S...n using proprietary taste receptor-based technolog...ood, beverage, and ingredient supply industries, t...ncial results for the third quarter ended Septembe...ird quarter of 2009, compared to $4.0 million for ...
Breaking Biology Technology:Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus 2GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14
...raTag(TM) technology,s ability to ...ANCISCO, Calif., May 16 Monogram,Biosciences, Inc...,collaborators will present results on HERmark(TM)...o measure HER2 and predict response to,Herceptin(R... cancer at the,upcoming 44th ASCO Annual Meeting t...
...r Aqua Bounty to scale back commitment to i... TSX symbol: SBS, CALGARY, May 1...,(TSX:SBS), a biotechnology company developing a p... cardiovascular diseases, today announced that,its... shrimp feed additive,program, Aqua Bounty Technol...
...oration,announced today that it has enrolled and r... IIb trial with oral larazotide acetate, an inhibi...atment of patients with active,celiac disease (CD)...d,placebo-controlled study will evaluate the clini...lity of larazotide acetate in 106 active CD,subjec...
Other Biology Technology:Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting 2Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting 3Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting 4Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting 5SemBioSys provides update on shrimp feed additive, Immunosphere(TM) 2SemBioSys provides update on shrimp feed additive, Immunosphere(TM) 3Alba Therapeutics Announces the Enrollment and Randomization of the First Patient in the Phase IIb Clinical Trial for Larazotide Acetate (AT-1001) for the Treatment of Active Celiac Disease 2Alba Therapeutics Announces the Enrollment and Randomization of the First Patient in the Phase IIb Clinical Trial for Larazotide Acetate (AT-1001) for the Treatment of Active Celiac Disease 3
Cassette, Hind III from Takara Mirus Bio
Cassette, EcoR I from Takara Mirus Bio
EcoR I Adaptors from Promega
Cassette, Sal I from Takara Mirus Bio
Biology Products: